Фармакоэкономический подход к терапиихронической обструктивной болезни легких
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Чучалин А.Г. и др. Практические рекомендации по диагностике, лечению, профилактике ХОБЛ. М., 2005.
2. Global Initiative for Chronic Оbstructive Lung Disease. 2009. www.goldcopd.org
3. Mannino DM et al. MMWR 2002; 51 (SS06): 1–16.
4. Пресс-выпуск ВЦИОМ №1234 от 29 мая 2009 г.
5. Чучалин А.Г. и др. Качество жизни больных хронической обструктивной болезнью легких в России: результаты многоцентрового популяционного исследования «ИКАР-ХОБЛ». Пульмонология. 2004; 1: 93–102.
6. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org
7. U.S. Department of Health and Human Services. National Institutes of Health. National Heart Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases.
8. GOLD executive summary. Am J Respir Crit Care Med 2007.
9. Halpin Proc Am Thoracic Soc 2006; 3: 227.
10. Dusser D et al. Eur Respir J 2006; 27: 547–55.
11. Powrie DJ et al. Eur Respir J 2007; 30: 1–8.
12. Casaburi R et al. Eur Respir J 2002; 19: 217–24.
13. Vincken W et al. Eur Respir J 2002; 19: 209–16.
14. Tashkin DP et al. UPLIFT Study Investigators. N Engl J Med 2008; 359: 1543–54.
15. Welte T et al. Am J Respir Crit Care Med 2009; 179: A6192.
16. Lo..fdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23 (4): 365–75.
17. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32–46.
18. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24.
19. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19 (2): 209–16.
20. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58 (5): 399–404.
21. Павленко С.С., Павленко Н.С., Куделя Л.М. и др. Пульмонология. 2005; 4: 92–6.
22. Miravitlles, Murio, Guerrero, Gisbert A. 1-Year Follow-up Study. Costs of Chronic Bronchitis and COPD: Chest 2003; 123: 784–91.
23. Laitinen et al. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998–2007. Resp Med 1999; 93 (5): 297–332.
2. Global Initiative for Chronic Оbstructive Lung Disease. 2009. www.goldcopd.org
3. Mannino DM et al. MMWR 2002; 51 (SS06): 1–16.
4. Пресс-выпуск ВЦИОМ №1234 от 29 мая 2009 г.
5. Чучалин А.Г. и др. Качество жизни больных хронической обструктивной болезнью легких в России: результаты многоцентрового популяционного исследования «ИКАР-ХОБЛ». Пульмонология. 2004; 1: 93–102.
6. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org
7. U.S. Department of Health and Human Services. National Institutes of Health. National Heart Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases.
8. GOLD executive summary. Am J Respir Crit Care Med 2007.
9. Halpin Proc Am Thoracic Soc 2006; 3: 227.
10. Dusser D et al. Eur Respir J 2006; 27: 547–55.
11. Powrie DJ et al. Eur Respir J 2007; 30: 1–8.
12. Casaburi R et al. Eur Respir J 2002; 19: 217–24.
13. Vincken W et al. Eur Respir J 2002; 19: 209–16.
14. Tashkin DP et al. UPLIFT Study Investigators. N Engl J Med 2008; 359: 1543–54.
15. Welte T et al. Am J Respir Crit Care Med 2009; 179: A6192.
16. Lo..fdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23 (4): 365–75.
17. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32–46.
18. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24.
19. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19 (2): 209–16.
20. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58 (5): 399–404.
21. Павленко С.С., Павленко Н.С., Куделя Л.М. и др. Пульмонология. 2005; 4: 92–6.
22. Miravitlles, Murio, Guerrero, Gisbert A. 1-Year Follow-up Study. Costs of Chronic Bronchitis and COPD: Chest 2003; 123: 784–91.
23. Laitinen et al. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998–2007. Resp Med 1999; 93 (5): 297–332.
Авторы
В.В.Архипов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.